Number Needed to Treat for Lithium in Bipolar Disorder
The NNT for lithium in acute mania is 5 (95% CI 3-20) when compared to placebo, meaning you need to treat 5 patients with lithium for one additional patient to achieve remission compared to placebo. 1
Acute Mania Treatment
The most robust meta-analysis examining lithium's efficacy in acute mania demonstrates clear superiority over placebo 1:
- Response rate ratio: 1.95 (95% CI 1.17-3.23) - patients are nearly twice as likely to respond to lithium versus placebo
- NNT: 5 (95% CI 3-20) for achieving remission
- Treatment periods in these trials ranged from 3-4 weeks
Comparative Efficacy Context
When lithium is compared to other mood stabilizers in acute mania 1:
- Lithium vs. chlorpromazine: NNT = 4 (95% CI 3-9), with patients twice as likely to achieve remission with lithium (rate ratio 1.96)
- Lithium vs. carbamazepine: No significant difference (rate ratio 1.01)
- Lithium vs. valproate: No significant difference (rate ratio 1.22)
- Lithium vs. haloperidol: Equivalent efficacy on global severity measures
Balancing Efficacy and Tolerability
A critical 2011 analysis provides important context for clinical decision-making by examining the likelihood to help or harm (LHH = NNH ÷ NNT) 2:
For acute mania, lithium demonstrates superior tolerability compared to other FDA-approved agents:
- Lithium NNH for sedation: 27 vs. 5-17 for other agents
- Lithium NNT for response: 4 vs. 4-8 for other agents
- Lithium LHH: 6.8 vs. 0.7-3.4 for other agents
This means lithium provides similar efficacy to other antimanic agents but with substantially less sedation, making it particularly valuable for patients who are sensitive to sedating effects or need to maintain daytime functioning.
Clinical Implementation Considerations
FDA-Approved Indications
Lithium is FDA-approved for acute mania and maintenance treatment in bipolar disorder, with approval extending down to age 12 years 3, 4. It remains the only agent with FDA approval for bipolar disorder in youth, though this was based historically on adult literature 4.
Dosing for Acute Mania
For acute mania, typical dosing is 600 mg three times daily, targeting serum levels of 1.0-1.5 mEq/L 3. Serum levels should be monitored twice weekly during the acute phase until stabilization occurs.
Response Timeline
When treating an acute manic episode, lithium typically produces normalization of symptoms within 1-3 weeks 3.
Important Caveats
Maintenance therapy considerations: While lithium shows clear efficacy in acute treatment, one controlled discontinuation trial in adolescents found high relapse rates in both lithium-continuation and placebo groups after acute stabilization, raising questions about ongoing efficacy in some populations 4. This suggests that acute response does not guarantee sustained benefit, and maintenance strategies may require combination approaches or alternative agents in certain patients.
Monitoring requirements: The NNT calculation reflects efficacy under controlled trial conditions with optimal monitoring. Real-world effectiveness depends on adequate serum level monitoring, patient adherence, and management of adverse effects 5.